Global Neuroprosthetics Market Size and Trends

The global neuroprosthetics market size is expected to reach US$ 26.12 Bn by 2030, from US$ 12.66 Bn in 2023, exhibiting a CAGR of 10.9% during the forecast period.

Global Neuroprosthetics Market- Drivers

Rising Prevalence of Neurological Disorders: The global neuroprosthetics market is being primarily driven by the rising prevalence of various neurological disorders across the world. Neurological disorders such as Parkinson's disease, epilepsy, essential tremor, dystonia, and Alzheimer’s disease are affecting a significant proportion of the global population. Just to give some perspective, it is estimated that over 50 million people are affected by epilepsy worldwide, and this number continues to rise each year. Similarly, over 10 million people are living with Parkinson's disease and this number is projected to double by 2040. Alzheimer’s disease, which is the most common form of dementia, affects over 50 million people globally, and this number is expected to rise multifold in the coming decades as average life expectancy increases.

The higher risks and incidences of such neurological conditions are fueling the need for developing advanced treatment methods. Neuroprosthetics are emerging as a breakthrough technology that can help improve the lives of people suffering from various neurological diseases and conditions. Implantable devices like deep brain stimulation systems have already found major success in effectively treating movement disorders like Parkinson’s disease. Ongoing research and clinical trials suggest that neuroprosthetics also hold promise for developing therapies for more complex conditions like Alzheimer’s, stroke, spinal cord injuries, and epilepsy. With limited treatment options currently available for several severe neurological disorders, neuroprosthetics are poised to transform the landscape of neurological healthcare in the coming years.

Technological Advancements: The neuroprosthetics industry has grown by leaps and bounds over the past decade, owing to significant technological advancements. Advancements in the fields of nanotechnology, biocompatible materials, neural engineering, and wireless communication systems have enabled the development of smarter and miniature neuroprosthetic devices. Contemporary systems are far more advanced and refined than early neuroprosthetics, which were bulky, invasive, and had short battery lives. Today’s devices feature miniaturized high-density electrode arrays, sophisticated electronics and software, wireless power transfer, biocompatible encapsulation, and enhanced integration with peripheral nervous systems.

Device manufacturers are continuously working to enhance the performance, computing power, bandwidth and sustainability of neuroprosthetic systems. For instance, researchers are developing neural interfaces made from bendable and flexible electronics that can conform better to brain surfaces. Technologies like optogenetics and high-density microelectrode arrays are augmenting our understanding of brain activity and neuronal pathways. The application of machine learning and big data techniques is further helping to improve prosthetic training, interfaces, and performance over time. Advancements are also being made in creating autonomous, implantable and wireless devices with vast potential for new neurotechnologies and clinical applications. Fueled by growing R&D investments, technological breakthroughs are certain to make neuroprosthetics more effective, reliable, and commercially viable solutions in the years to come.

Government and private funding for research: Government and private funding for neuroprosthetic research is fueling the expansion of the global neuroprosthetics market. Both public and private investment in this field has increased substantially over the past few years as the potential for life-changing technologies continues to emerge.

In addition to government grants, private donors and ventures are also injecting substantial capital into neuroprosthetics companies and university laboratories. Elon Musk’s Neuralink raised over US$ 500 million in private funding as of 2021 to develop implantable brain-machine interfaces. Other pioneers, such as Synchron and Blackrock Microsystems, routinely receive angel investments for their work developing neural interfaces. Corporate partnerships between academic research bodies and medical device giants like Medtronic and Boston Scientific serve to expedite the translation of neuroprosthetics prototypes into real-world technologies.

Global Neuroprosthetics Market- Opportunities

Customization and miniaturization of neuroprosthetic devices: Customization and miniaturization of neuroprosthetic devices present a great opportunity in the global neuroprosthetics market. With advancements in materials science, 3D printing, flexible and stretchable electronics, neural interfaces are becoming more personalized and less invasive. Implant sizes are shrinking, which allows for improved targeting of neural structures and minimally disruptive integration with the native nervous system. Researchers are working on novel solutions such as high-density electrode arrays, hybrid bioelectronic devices, and neural dust - extremely small untethered sensors that can be implanted throughout the body and brain to precisely monitor and modulate neural activity.

As these devices become smaller, less complex to implant, and able to interface with more discrete brain regions, they open up the possibility of treating numerous currently untreatable neurological and neuropsychiatric conditions. Miniaturized neural interfaces show promise for restoring sensory and motor function in spinal cord injury, improving speech and mobility outcomes for stroke patients, assisting with epilepsy management, reducing tremors for Parkinson’s disease patients, and alleviating chronic pain. Customization allows prosthetics to be tailored for each individual's unique neural geography and physiology. This personalized approach could provide more effective symptom control and superior quality of life improvements for patients compared to one-size-fits-all treatment alternatives.

Rising Healthcare Expenditure: One of the significant factors influencing the growth rate of the global neuroprosthetics market is the growing healthcare expenditure, which helps in improving its infrastructure. For instance, according to the International Health Care System of the U.S., in June 2020, U.S. government organizations aim to improve the healthcare infrastructure by increasing funding, setting legislation and national strategies, and cofounding and setting basic requirements and regulations for the Medicaid program. Similarly, in November 2022, the Canadian Institute for Health Information reported that the total health spending in Canada was US$ 331 billion in 2022, or US$ 8,563 per Canadian, while health expenditure represented 12.2% of Canada’s gross domestic product (GDP) in 2022, following a high of 13.8% in 2020.
Advancements in brain-computer interface technology: Advancements in brain-computer interface technology hold tremendous opportunities for growth in the global neuroprosthetics market in the coming years. Brain-computer interfaces (BCIs) allow direct communication pathways between the brain and an external device, and recent breakthroughs have improved both the quality of the signal decoding and interfaces between the brain and computers. BCIs decode neuron firing patterns in brain areas related to movement and translate them into commands for an external device, such as a prosthetic arm. Researchers have demonstrated BCIs that can successfully translate brain signals related to imagined movements in real-time with improved accuracy compared to several years ago.

BCIs offer hope to patients suffering from severe neuromuscular disabilities by providing them with restored capabilities they had lost. Successfully demonstrating devices that can restore aspects of mobility, dexterous manipulation, and communication could reshape the neuroprosthetics market. For example, clinical trials are underway evaluating the ability of BCIs to allow people with tetraplegia to operate prosthetic arms or wheelchairs solely through their brain activity. If these trials continue to show promise in restoring functions patients need in daily lives, it may encourage greater adoption of the technology. The potential for BCIs to improve quality of life for those with impaired mobility and interaction with the physical world represents a huge growth opportunity.

Figure 2. Global Neuroprosthetics Market Share (%), By Type, 2023

Global Neuroprosthetics Market- Recent Developments

Product Launch and Approval

In November 2022, Cochlear Limited, the global leader in implantable hearing solutions, received U.S. Food and Drug Administration (FDA) approval for the CochlearTM Nucleus 8 Sound Processor. The Nucleus 8 Sound Processor is the smallest and lightest behind-the-ear cochlear implant sound processor available in the industry.
In October 2022, Axoft, a neurotechnology company, announced the launch of its brain-machine interface (BMI) to better treat neurological disorders. It was launched through a U.S. Food and Drug Administration (FDA) breakthrough device designation. The company secured USD 8 million in capital to fund pre-clinical studies with the U.S. FDA and to scale up prototypes of its neural implants.

Business Development Activities by the Market Players

In December 2022, the Government of Saskatchewan, through the Ministry of Health and the Saskatchewan Health Authority (SHA), implemented the expanded Cochlear Implant Program to help those who needed their external sound processor replaced. Under the new program, individuals will co-pay US$ 840 per implant, with the Ministry of Health covering the remainder of the cost, which is often US$ 8,000 to US$ 12,000.
In April 2021, Rice University and Houston Methodist, a research center, announced a partnership to launch the Center for Translational Neural Prosthetics and Interfaces, which brings together scientists, clinicians, engineers, and surgeons to solve clinical problems with neurorobotics.